Rare genetic disease has a surprising weak point scientists can target

Friedreich's ataxia is the kind of diagnosis that reshapes a life. People usually start noticing symptoms between ages 5 and 15—progressive loss of coordination, muscle weakness, vision problems. There's no cure, no reliably effective treatment, and most people don't make it past their 40s. But researchers at Massachusetts General Hospital just found something unexpected: a genetic lever that, when pulled the right way, helps cells survive the damage this disease causes.

The breakthrough came from studying a protein called FDX2. When scientists reduced its levels in cells and in mice with Friedreich's ataxia, neurological symptoms improved. It's not a cure, but it's a tangible new direction for a disease that has had almost nowhere to turn.

How a rare disease breaks cells

Friedreich's ataxia happens when the body doesn't make enough frataxin, a protein that lives inside mitochondria—the energy factories of our cells. Without frataxin, cells can't properly assemble iron-sulfur clusters, the molecular structures they need to generate energy. Over time, this energy crisis damages neurons, particularly in the spinal cord and brain.

To find a way around this problem, Joshua Meisel and his team at MGH (now at Brandeis University) used a clever experimental trick. They created roundworms that lacked frataxin entirely and kept them alive in low-oxygen conditions—a setup that mimicked how the disease damages cells. Then they let the worms adapt. Some survived and evolved genetic changes that compensated for the missing protein.

When the team sequenced these survivor worms, they found mutations in two genes: FDX2 and NFS1. The mutations worked by helping cells make iron-sulfur clusters even without frataxin. But here's the key insight: excessive FDX2 actually gets in the way. Reducing it—either by mutating the gene or removing one of two copies—restored the balance.

"The balance between frataxin and FDX2 is key," said Vamsi Mootha, the senior researcher on the study. "When you are born with too little frataxin, bringing down FDX2 a bit helps."

Why this matters for treatment

The finding is significant because FDX2 isn't some obscure protein with no pharmaceutical options. It's a protein that drug developers know how to target using conventional medicines. That means researchers don't have to start from scratch inventing entirely new drug classes. They can use existing tools.

The team tested their hypothesis in human cells and mice. In the mouse model of Friedreich's ataxia, reducing FDX2 led to measurable improvements in neurological function. It's early evidence, but it's the kind of early evidence that opens doors.

The researchers are careful to note that this isn't a finished solution. The ideal balance between frataxin and FDX2 likely varies from person to person. More work is needed to understand how this balance works in human biology, and additional safety and efficacy testing will be essential before any human trials. But for a disease with almost no options, a new direction—especially one grounded in real cellular biology—changes the conversation.

What happens next depends on whether this finding can move from mice to humans. That's the long road ahead. But for people living with Friedreich's ataxia and their families, knowing that researchers found a genuine weak point in the disease is the kind of news that matters.